Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Schrag is a neuroscientist at Vanderbilt University Medical Center who assisted with the autopsy of one of the patients who died in Eisai’s trial and has contributed to investigations of ...

Eisai, though, was pinning its hopes on Leqembi. The same year as the Honolulu conference, researchers from 19 drug, biotech and medical companies came together at a Phoenix airport hotel for a ...

medical office personnel, and caregivers.” Eisai has predicted that peak sales for the drug in Japan could be around $675 million, according to a Reuters report, which said Eisai is hoping to ...

TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...

Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...

If the European Commission decides to grant sales of the medicine, it will be the first Alzheimer's medicine available in the ...

STOCKHOLM, Nov. 7, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook for Leqembi for their 2024 fiscal year (FY), which runs ...